ABVX:EPA
Abivax SA
၈၃.၅၀ €
arrow_downward
-၀.၇၇%(-၀.၆၅) 1D
အောက် ၂, GMT+၂ ၁၇:၃၅:၂၃ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
၈၃.၆၅ €
High
၈၅.၂၀ €
Low
၈၂.၈၀ €
Mkt. cap
၇၁၉.၆၁ ဋေ
Avg. vol.
၁.၅၅ သိန်း
Volume
၁.၂၀ သိန်း
52-wk high
၁၃၉.၀၀ €
52-wk low
၆၀.၄၅ €
EPS
-၅.၂၀ €
Shares outstanding
၈.၇၅ ကုဋေ
No. of employees
၉၈
Open
၈၃.၆၅ €
High
၈၅.၂၀ €
Low
၈၂.၈၀ €
Mkt. cap
၇၁၉.၆၁ ဋေ
Avg. vol.
၁.၅၅ သိန်း
Volume
၁.၂၀ သိန်း
52-wk high
၁၃၉.၀၀ €
52-wk low
၆၀.၄၅ €
EPS
-၅.၂၀ €
Shares outstanding
၈.၇၅ ကုဋေ
No. of employees
၉၈
News stories
From web sources and news partners
Foreign Policy Journal
·
ပြီးခဲ့သည့် ၅၃ မိနစ်
Supreme Court Cases Involving Apple (NASDAQ: AAPL), Exxon (NYSE: XOM), And Intel (NASDAQ: INTC) Could Reshape Investor Portfolios
Simply Wall Street
·
ပြီးခဲ့သည့် ၁၃ မိနစ်
October 2026 Founder Led Stocks To Watch
Yahoo! Finance Canada
·
ပြီးခဲ့သည့် ၁၉ မိနစ်
NTHI,HERZ,TRIN,EFOR,FFIN,NXRT,GO,BLCO,CULP,VSNT,KWY,FRST,VIRC,ENTX,BLIN,GRNT,SSP,GAIA,NRGV,AFCG,APCX,THRY,KLTR,BETR | Stock Prices | Quote Comparison
AOL.com
·
ပြီးခဲ့သည့် ၄ နာရီ
Forget the S&P 500: SCHD Is Beating It by Nearly 10 Points in 2026 and Its Dividend Just Grew
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees၉၈
Founded၂၀၁၃ ဒီ ၄
Headquarters-
Sector-
Websiteabivax.com